Archive · 16 Sep 2026
Molbio Diagnostics Shares Fall After Strong Post-Listing Rally
Molbio Diagnostics is a healthcare company whose shares recently rose very quickly.
After that big rise, many investors sold shares to lock in profits.
This caused the stock to fall for two days in a row.
It dropped as much as 8.8% on September 16 and was down 18.5% across the two sessions.
Even after falling, the shares were still more than 50% above their IPO price.
The company also reported a much better financial quarter than the same period last year.
Its profit was ₹58.74 crore, and its revenue increased sharply.
Company managers expect sales to grow by 25% in FY27, but they say results may differ from quarter to quarter.
Molbio Diagnostics shares fell as much as 8.8% to ₹1,229.65 on September 16, extending their decline to 18.5% over two sessions.
The sell-off followed a 75% one-month rally and the stock’s 52-week high of ₹1,686.50 on September 11.
Despite the correction, shares remained more than 50% above the ₹807 IPO price and had listed at ₹980.
For the April-June FY27 quarter, consolidated net profit reached ₹58.74 crore, compared with a ₹23.74 crore loss a year earlier.
Revenue from core operations rose 309% year over year to ₹408 crore, while EBITDA turned positive at ₹101 crore with a 25.20% margin.
- Who
- Molbio Diagnostics and investors trading its shares.
- What
- Molbio Diagnostics shares fell sharply after a strong post-listing rally, despite improved quarterly financial results.
- When
- The latest decline occurred on September 16, following a two-session fall; the shares listed on August 17, 2026, according to the article.
- Where
- On the Indian stock exchanges, including the BSE and NSE.
- Why
- Investors appeared to book profits after the stock’s rapid rise, while the company’s financial performance and management outlook had supported earlier gains.
Profit-Booking View
Growth-Outlook View
Reason for the share-price decline
Profit-Booking View
Investors sold shares to book profits after a rapid rally, leading to an 18.5% fall over two sessions.
Growth-Outlook View
The correction occurred despite strong reported earnings and management’s positive full-year guidance.
How to view the stock’s performance
Profit-Booking View
The recent decline erased a significant part of the stock’s short-term gains and followed its September 11 record in the article.
Growth-Outlook View
The shares remained more than 50% above the ₹807 IPO price and had gained 75% in the month before the correction.
Quarterly performance interpretation
Profit-Booking View
Management cautioned that public-health procurement makes the business’s quarterly results non-linear, so individual quarters may not show the full picture.
Growth-Outlook View
The latest quarter showed a turnaround, with ₹58.74 crore profit, 309% revenue growth and a 25.20% EBITDA margin.
- Intraday decline
- As much as 8.8%, to ₹1,229.65 per share on the BSE
- Two-session decline
- 18.5%
- IPO issue price
- ₹807 per share
- Listing price
- ₹980 per share, a 21.44% premium to the issue price
- FY27 first-quarter net profit
- ₹58.74 crore, versus a ₹23.74 crore loss a year earlier
- FY27 first-quarter revenue
- ₹408 crore, up 309% year over year
- Management guidance
- 25% topline growth and a 24-25% EBITDA margin for FY27